Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Jun 21, 2021

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

May 12, 2021

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

May 07, 2021

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

May 06, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

May 06, 2021

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

Apr 29, 2021

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET

Apr 09, 2021

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

Mar 24, 2021

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

Mar 18, 2021

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

Mar 04, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 29

Investor Tools

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact